Figure 3.
(A) Heat map of the activity of 114 NCI oncology drugs associated with each of the four pancreatic cancer-associated cells in 3D and 2D formats assessed by corresponding log IC50 values (red = increased potency; green = decreased potency). The responses to the most potent drugs, trametinib, romidepsin, bortezomib, carfilzomib, and homoharringtonine, plus gemcitabine, the first-line drug for treating pancreatic cancer, are highlighted below the graph. (B) The correlation plot of the percent inhibition values of the approved drug library tested at 2 µM in the 3D and 2D models of each pancreatic cancer-associated cell.